See more : Global Lights Acquisition Corp Ordinary Shares (GLAC) Income Statement Analysis – Financial Results
Complete financial analysis of Neoleukin Therapeutics, Inc. (NLTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neoleukin Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Cinevista Limited (CINEVISTA.BO) Income Statement Analysis – Financial Results
- Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS) Income Statement Analysis – Financial Results
- Voice Assist, Inc. (VSST) Income Statement Analysis – Financial Results
- Mountain & Co. I Acquisition Corp. (MCAAU) Income Statement Analysis – Financial Results
- Polson Limited (POLSON.BO) Income Statement Analysis – Financial Results
Neoleukin Therapeutics, Inc. (NLTX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neoleukin.com
About Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 6.00K | 451.00K | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 6.00K | 451.00K | 0.00 | 25.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 41.13M | 39.16M | 24.34M | 4.42M | 41.79M | 36.27M | 28.38M | 15.80M | 18.08M | 7.54M | 6.05M |
| General & Administrative | 17.97M | 21.54M | 17.21M | 18.83M | 15.84M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.97M | 21.54M | 17.21M | 18.83M | 15.84M | 14.85M | 9.26M | 5.54M | 4.30M | 1.78M | 1.64M |
| Other Expenses | -42.00K | 6.00K | -44.00K | -8.00K | -445.00K | -39.00K | -43.00K | -369.00K | -254.89K | 0.00 | 64.03K |
| Operating Expenses | 59.10M | 60.70M | 41.55M | 23.24M | 57.62M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M |
| Cost & Expenses | 59.10M | 60.70M | 41.55M | 23.24M | 57.62M | 51.12M | 37.65M | 21.34M | 22.38M | 9.38M | 7.68M |
| Interest Income | 1.58M | 19.00K | 490.00K | 1.54M | 1.56M | 998.00K | 619.00K | 0.00 | 0.00 | 26.32K | 0.00 |
| Interest Expense | 1.58M | 0.00 | 0.00 | 1.00K | 4.00K | 4.00K | 1.00K | 99.00K | 461.59K | 42.92K | 9.47K |
| Depreciation & Amortization | 2.61M | 2.28M | -13.84M | 49.59M | 1.04M | 940.00K | 644.00K | -421.00K | 135.95K | 59.57K | 130.78K |
| EBITDA | -56.49M | -60.70M | -47.56M | -21.37M | -31.51M | -50.16M | -37.07M | -21.71M | -24.38M | -9.68M | -7.53M |
| EBITDA Ratio | 0.00% | -1,011,633.33% | -10,546.34% | 0.00% | -126.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -59.10M | -60.70M | -33.73M | -70.96M | -32.62M | -51.12M | -37.65M | -21.34M | -23.57M | -9.38M | -7.66M |
| Operating Income Ratio | 0.00% | -1,011,633.33% | -7,478.49% | 0.00% | -130.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.54M | 6.00K | 7.83M | 1.52M | 1.04M | 936.00K | 643.00K | -520.00K | 487.60K | 641.24K | -9.47K |
| Income Before Tax | -57.56M | -60.69M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -24.03M | -8.73M | -7.67M |
| Income Before Tax Ratio | 0.00% | -1,011,533.33% | -7,378.49% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.54M | -2.28M | -8.32M | -7.00K | -1.04M | -940.00K | -644.00K | 421.00K | -222.00 | -5.04K | 42.29K |
| Net Income | -56.02M | -58.42M | -24.96M | -69.44M | -31.59M | -50.18M | -37.00M | -21.86M | -23.82M | -9.30M | -12.14M |
| Net Income Ratio | 0.00% | -973,583.33% | -5,533.48% | 0.00% | -126.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| EPS Diluted | -1.01 | -1.06 | -0.48 | -2.57 | -1.34 | -2.14 | -1.96 | -1.73 | -2.75 | -0.93 | -2.08 |
| Weighted Avg Shares Out | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M | 4.69M | 3.78M | 2.53M | 1.73M | 1.17M | 1.17M |
| Weighted Avg Shares Out (Dil) | 11.04M | 11.01M | 10.37M | 5.41M | 4.70M | 4.69M | 3.78M | 2.53M | 1.73M | 1.17M | 1.17M |
IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week
COVID-19's impact Global Monoclonal Antibodies Market 2020 Segmented by Application and Geography Trends, Growth and Forecasts to 2025
Trust Co. of Oklahoma Takes $347,000 Position in Novo Nordisk A/S (NYSE:NVO)
European stocks rise on upbeat forecasts from Pandora, Novo Nordisk
Recombinant Protein Market 2020 Size, Share, Global Trends, In-Depth Research Study, Development Status, Opportunities, Future Plans, Competitive Landscape and Growth by Forecast 2026 | Impact of COVID-19 on the industry
Novo Sees Possibility for Significant Growth at Beatons Creek
BiomX Appoints Paul Sekhri and Alan Moses, M.D., to Board of Directors
Source: https://incomestatements.info
Category: Stock Reports